Delinkage no panacea for access to medicines
The delinkage agenda under discussion in Geneva, while well-intentioned, is a distraction from practical solutions to increase access to medicines.
Enantiomer patents – a necessary incentive
Understanding how exactly these structurally similar molecules work on the human body requires significant investments of time, money and expertise, write Jack Ellis and Philip Stevens.
Second medical uses for existing drugs
Patents are necessary to incentivise research into this vital area of medicine, write Philip Stevens and Jack Ellis
The power of combination drugs
Combining different drugs into a single pill can have enormous therapeutic benefits but research and development is difficult and costly, write Philip Stevens and Jack Ellis
Trump should seek rules to protect intellectual property in the modern era
Global IP rules need a refresh to take account of rapidly changing technology, write Philip Stevens and Nigel Cory.
The Commission’s innovation confusion
The European Commission is undermining innovation on the continent through its contradictory policy making around innovation.
Una oportunidad biotecnológica para Colombia
El país podría construir una bioeconomía si trabajara en reducir las barreras regulatorias. Por ejemplo, en promedio toma 225 días para que el gobierno apruebe una prueba clínica. En Singapur es menos de un mes.
WTO TRIPS Agreement spurs innovation in the Indian biopharmaceutical industry
The upgrading of India’s IP laws as a result of its WTO commitments has confounded sceptics by encouraging its generics companies to move towards innovation.
Innovación biofarmacéutica en México: ¿sabrá el país aprovechar su potencial?
Hace casi una década, la empresa de servicios tecnológicos de salud IMS Health seleccionó 21 países que describió como “farmaemergentes” – países en desarrollo con industrias farmacéuticas con importancia creciente, entre los cuales se encontraba México.